Targeted Fusion Biopsy of the Prostate

• Status: Completed
• Trial end date: 2018-03-31
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to see if using Positron Emission Tomography (PET) scan and transrectal ultrasound (TRUS) guided biopsy together (creating a 3-dimensional ultrasound) will detect prostate cancer more accurately than the standard 2-dimensional approach which uses only the TRUS to guide the biopsy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Emory University
• Collaborator: National Cancer Institute (NCI)

Criteria

Inclusion Criteria:

• Have been originally diagnosed with prostate carcinoma and have undergone definitive non-prostatectomy therapy for localized disease

• There is suspicion of recurrent prostate carcinoma as defined by: Older American Society for Radiation Oncology (ASTRO) criteria of three consecutive rises of prostate-specific antigen (PSA) or earlier if clinically appropriate, and/or nadir + 2.0 ng/ml (Radiation Therapy Oncology Group (RTOG)-ASTRO Phoenix criteria)

• Able to provide written informed consent

Exclusion Criteria:

• Cryotherapy, external beam radiation, or high intensity focused ultrasound (HIFU) within the past year

• Brachytherapy within the past two years (to rule out a transient rise in PSA)

• Prostate biopsy within the past month (to decrease a false positive result due to inflammation)

• Not otherwise eligible for prostate biopsy